Abstract
The number of CoViD-19 deaths more reliably tracks the progression of the disease across populations than the number of confirmed cases. Substantial age and sex differences in CoViD-19 death rates imply that the number of deaths should be adjusted not just for the total size of the population, but also for its age-and-sex distribution. Following well-established practices in demography, this article discusses several measures based on the number of CoViD-19 deaths over time and across populations. The first measure is an unstandardized occurrence/exposure rate comparable to the Crude Death Rate. To date, the highest value has been in New York, where at its peak it exceeded the state 2017 Crude Death Rate. The second measure is an indirectly standardized rate that can be derived even when the breakdown of CoViD-19 deaths by age and sex required for direct standardization is unavailable. For populations with such breakdowns, we show that direct and indirect standardization yield similar results.
Standardization modifies comparison across populations: while New Jersey now has the highest unstandardized rate, Baja California (Mexico) has the highest standardized rate. Finally, extant life tables allow to estimate reductions in life expectancy at birth. In the US, life expectancy is projected to decline this year by more (-.68) than the worst year of the HIV epidemic, or the worst three years of the opioid crisis, and to reach its lowest level since 2008. Substantially larger reductions, exceeding two years, are projected for Ecuador, Chile, New York, New Jersey and Peru.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Publicly available data only
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6